



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** March 26, 2010

**To:** Primary Clinical Research Associates

**From:** Janis Wobschall  
Research Protocol Specialist

**Re:** N0776, Phase II Trial of Avastin® in Combination with Sorafenib in Recurrent Glioblastoma Multiforme

The following forms have been updated:

<b>CRF Title</b>	<b>Brief Description of Edit</b>
End of Active Treatment/Cancel Notification Form	<ul style="list-style-type: none"><li>Removed "Observation" as a choice for where patients go after treatment ends.</li></ul>
Fax Supply Order Form	<ul style="list-style-type: none"><li>Updated to reflect Biospecimen Accessioning Processing rather than Mayo Medical Laboratory.</li></ul>
Reimbursement Request Form	<ul style="list-style-type: none"><li>The Max number per patient" column has been updated to be in-line with the protocol.</li></ul>

If you have any questions, please feel free to contact me.

Enclosure